Featured Research

1 of 16, Fig. 1 Administration of AAV9.LAMP2B in adult (6-month-old) mice shows dose-dependent expression of human LAMP2B in heart tissue from Lamp2 KO mice together with an improvement in autophagic flux and cardiac function.

Systemic AAV9.LAMP2B injection reverses metabolic and physiologic multiorgan dysfunction in a murine model of Danon disease

2 of 16, Fig. 1. Study selection flow diagram. Identification, screening, and inclusion process through Medline and EMBASE databases that led to the inclusion of 146 clinical cases of Danon Disease in the study. DD = Danon disease.

Danon disease: Gender differences in presentation and outcomes

3 of 16, Fig. 1. Mitochondrial abnormalities and incomplete mitophagy in Danon hiPSC-CMs.

Impaired mitophagy facilitates mitochondrial damage in Danon disease

4 of 16, Figure 1 LAMP-2 deficient induced pluripotent stem…

Brief Report: Oxidative Stress Mediates Cardiomyocyte Apoptosis in a Human Model of Danon Disease and Heart Failure

Methods for the treatment of Danon disease and other disorders of autophagy. Provisional Patent Application Serial No. 62/280,269

6 of 16, Fig. 1: Novel TPM1 and VCL variants together cosegregate with family members exhibiting cardiomyopathy.

Combinatorial interactions of genetic variants in human cardiomyopathy

Induced pluripotent stem cells for the study of cardiovascular disease

Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome

The cardiomyocyte lineage is critical for optimization of stem cell therapy in a mouse model of myocardial infarction

10 of 16, Figure 1: Specification of the cardiac lineage from human ESCs.

Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population

Serial in vivo positive contrast MRI of iron oxide-labeled embryonic stem cell-derived cardiac precursor cells in a mouse model of myocardial infarction

Specification of multipotential cardiovascular progenitor cells during embryonic stem cell differentiation and embryonic development

13 of 16, Figure 1. Institutional protocol related to the receipt of a hepatitis C virus (HCV) viremic (i.e., nucleic acid testing [NAT+]) organ.

Outcomes of heart transplantation from hepatitis C virus-positive donors

Fulminant Versus Acute Nonfulminant Myocarditis in Patients With Left Ventricular Systolic Dysfunction

15 of 16, Figure 1. Flow chart demonstrating derivation of the study population.

Outcomes of Acute Myocardial Infarction in Heart Transplant Recipients

$16 of 16, Figure 1. Flow Diagram of Enrollment, Randomization, Follow-up, and Analysis CVA indicates cerebrovascular accident; D4 + 5, doses 4 and 5; dP/dt, rate of left ventricular (LV) pressure development and decay; EF, ejection fraction; ETT, exercise treadmill test; and IC, intracoronary.$